Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2019 09:00 ET | Source: Aptevo Therapeutics Inc.

Aptevo Therapeutics Reports IXINITY® and Pipeline Progress

Reports 73% Increase in IXINITY Year-Over-Year Quarterly Net Revenue in Q1 2019 Anticipates Launching New IXINITY 3,000 IU Assay Mid-2019 Advances Dosing in Additional Cohorts in APVO436 and...
April 02, 2019 09:02 ET | Source: Aptevo Therapeutics Inc.

Aptevo Therapeutics Presents New Preclinical Data for APVO436 and ALG.APV-527 at the American Association for Cancer Research 2019 Annual Meeting

APVO436 Preclinical Data Continue to Show Promising Results Supporting Clinical Development for the Treatment of Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS) and...
March 25, 2019 09:02 ET | Source: Aptevo Therapeutics Inc.

Aptevo Therapeutics to Present New Preclinical Data for APVO436 and ALG.APV.527 at the American Association for Cancer Research 2019 Annual Meeting

SEATTLE, March 25, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today...
March 20, 2019 09:02 ET | Source: Aptevo Therapeutics Inc.

Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases

Unique Mechanism of Action Suppresses Inflammation and Immune Activation Without Promoting Pro-Inflammatory Lymphocyte Stimulation Preliminary Phase 1 Data Read-outs Anticipated Q3 and Q4 2019 ...
March 18, 2019 09:00 ET | Source: Aptevo Therapeutics Inc.

Aptevo Therapeutics Reports 2018 Financial Results and Provides Business Update

Achieves Record Annual IXINITY® Net Revenue of $23.1 Million Representing 111% Increase Over 2017 Advances APVO436 Into Phase 1/1b Clinical Trial for Treatment of Acute Myeloid Leukemia and...
March 07, 2019 09:13 ET | Source: Aptevo Therapeutics Inc.

Aptevo Announces Pricing of $22 Million Offering of Common Stock and Warrants

SEATTLE, March 07, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today...
March 06, 2019 16:37 ET | Source: Aptevo Therapeutics Inc.

Aptevo Announces Proposed Public Offering of Common Stock and Warrants

SEATTLE, March 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today...
January 07, 2019 08:30 ET | Source: Aptevo Therapeutics Inc.

Aptevo Therapeutics Highlights Key 2019 Priorities

ADAPTIR™ Bispecific Antibody Candidates Poised to Progress in Clinical Development APVO436 Advancing in Phase 1 Clinical Trial for Acute Myeloid Leukemia;APVO210 Beginning Phase 1 Clinical Trial in...
January 03, 2019 09:02 ET | Source: Aptevo Therapeutics Inc.

Aptevo Therapeutics Collects $3.3 Million In Escrow Funds From Saol Therapeutics

SEATTLE, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that it...
December 21, 2018 09:00 ET | Source: Aptevo Therapeutics Inc.

Aptevo Therapeutics Announces Up To $35 Million Common Stock Purchase Agreement With Lincoln Park Capital

Provides Opportunistic Capital of up to $35 Million to Aptevo During the 36-month Term of the Agreement SEATTLE, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a...